Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA

Zaffuto, Emanuele; Gazdovich, Stéphanie; Leyh-Bannurah, Sami-Ramzi; Huland, Hartwig; Abdollah, Firas; Shariat, Shahrokh F.; Menon, Mani; Briganti, Alberto; Montorsi, Francesco; Karakiewicz, Pierre I.

doi:10.1111/iju.13261

Cited by 17 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence and mortality rates of BLCA patients are higher in elderly people. 40 The higher mortality rate in the elderly can be explained by several reasons. Elderly BLCA patients have increased genetic aberrations and tend to exhibit a poor-differentiated histology and a more aggressive phenotype.…”

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

152

120

View full text Add to dashboard Cite

The transition from non–muscle‐invasive bladder cancer (NMIBC) to muscle‐invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial‐mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT‐related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease‐free survival (DFS) than those with low risk scores. The EMT‐related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT‐related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT‐related gene signature that has tumour‐promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA.

show abstract

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

152

120

View full text Add to dashboard Cite

show abstract

“…Sarcomatoid-variant urothelial carcinoma is an uncommon histological variant of urothelial carcinoma [ 4 ]. The majority of sarcomatoid-variant urothelial carcinomas is found in the bladder, accounting for less than 1.0% of all bladder cancer cases [ 5 , 6 ]. Generally, sarcomatoid carcinoma is a biphasic malignant tumor exhibiting morphological and/or immunohistochemical evidence of epithelial and mesenchymal differentiation.…”

Section: Discussionmentioning

confidence: 99%

Sarcomatoid Variant of Bladder Carcinoma: A Case Report

et al. 2018

View full text Add to dashboard Cite

A 59-year-old man was referred to our hospital complaining of asymptomatic gross hematuria. Cystoscopy revealed a papillary tumor 8 cm in diameter filling the bladder. The patient underwent transurethral resection of the bladder tumor. The pathological findings revealed the sarcomatoid variant of urothelial carcinoma with a heterologous osteosarcomatous element. He had no metastasis according to our imaging analyses; thus, we planned radical cystectomy after two courses of neoadjuvant chemotherapy (gemcitabine and cisplatin). Following chemotherapy, enlarged pelvic lymph nodes were noted, and extremely aggressive local progression of the bladder tumor was confirmed. The patient ultimately died 6 months after his initial visit to our hospital.

show abstract

“…Several studies showed that these histological variants resulted in worse pathological features and/or survival outcomes, relative to UCUB. [2][3][4][5][6][7][8] NCCN guideline recommendations for treatment of non-UCUB vary according to histological variants. 9 RC with neoadjuvant CHT is recommended for NC patients.…”

Section: Introductionmentioning

confidence: 99%

Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non‐urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes

et al. 2020

Self Cite

View full text Add to dashboard Cite

Abbreviations & Acronyms AC = adenocarcinoma CHT = chemotherapy CSM = cancer-specific mortality EAPC = estimating annual percentage changes HR = hazard ratio ICD-O = international classification of disease for oncology IQR = interquartile range LNI = lymph node invasion MMT = multimodality treatment NC = neuroendocrine carcinoma NCCN = National Comprehensive Cancer Network NCDB = national cancer database OM = overall mortality RC = radical cystectomy RT = radiotherapy SCC = squamous cell carcinoma SEER = Surveillance, Epidemiology and End Results UCUB = urothelial carcinoma of the urinary bladder Correspondence: Francesco A Mistretta M.D., Cancer Prognostics and Health Outcomes Unit,Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality. Methods: Within the Surveillance, Epidemiology and End Results database (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015), 887 pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Kaplan-Meier plots, and univariable and multivariable Cox regression analyses focused on cancer-specific mortality rates. Results: Squamous cell carcinoma was recorded in 499 (56.3%) patients, neuroendocrine carcinoma in 246 (27.7%) and adenocarcinoma in 142 (16.0%). The highest proportion of multimodality treatment patients was recorded in neuroendocrine carcinoma (69.1%), relative to adenocarcinoma (34.5%) and squamous cell carcinoma (26.4%). A statistically significant annual increase was recorded in multimodality treatment rates in neuroendocrine carcinoma patients (46.7-74.2%, P < 0.01), but not in adenocarcinoma or squamous cell carcinoma patients. The 5-year cancer-specific mortality rate in neuroendocrine carcinoma patients was significantly lower after multimodality treatment versus radical cystectomy alone (37.0% vs 51.5%; P < 0.01), but no statistically significant differences were recorded in both adenocarcinoma (46.1% vs 35.5%; P = 0.8) and squamous cell carcinoma (41.4% vs 31.1%; P = 0.8) patients. In multivariable analyses, for neuroendocrine carcinoma patients, multimodality treatment was an independent predictor of a lower cancer-specific mortality rate (hazard ratio 0.58, P = 0.03). Conclusions: Multimodality treatment has been increasingly used during the study period in neuroendocrine carcinoma patients, and it has translated into a cancer-specific mortality benefit. This is not the case for other non-urothelial carcinoma of urinary bladder patients, such as adenocarcinoma or squamous cell carcinoma.

show abstract

Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA

Abstract: In bladder cancer, adenocarcinoma presents at higher stages than urothelial carcinoma. However, cancer-specific mortality rates do not differ. A more unfavorable stage at diagnosis and higher cancer-specific mortality apply to the signet-ring cell variant.

Cited by 17 publications

References 26 publications

An EMT‐related gene signature for the prognosis of human bladder cancer

An EMT‐related gene signature for the prognosis of human bladder cancer

Sarcomatoid Variant of Bladder Carcinoma: A Case Report

Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non‐urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes

Contact Info

Product

Resources

About